180 related articles for article (PubMed ID: 37954907)
61. Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.
Fabrizio VA; Curran KJ
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101305. PubMed ID: 34625231
[TBL] [Abstract][Full Text] [Related]
62. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
63. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
[TBL] [Abstract][Full Text] [Related]
64. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
Bader P; Rossig C; Hutter M; Ayuk FA; Baldus CD; Bücklein VL; Bonig H; Cario G; Einsele H; Holtick U; Koenecke C; Bakhtiar S; Künkele A; Meisel R; Müller F; Müller I; Penack O; Rettinger E; Sauer MG; Schlegel PG; Soerensen J; von Stackelberg A; Strahm B; Hauer J; Feuchtinger T; Jarisch A
Blood Adv; 2023 Jun; 7(11):2436-2448. PubMed ID: 36607834
[TBL] [Abstract][Full Text] [Related]
65. Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective.
Wang XJ; Wang YH; Ong MJC; Gkitzia C; Soh SY; Hwang WYK
Clinicoecon Outcomes Res; 2022; 14():333-355. PubMed ID: 35535300
[TBL] [Abstract][Full Text] [Related]
66. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
[TBL] [Abstract][Full Text] [Related]
67. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
Eigendorff F; Filimonova I; Scholl S; Sayer-Klink A; Rummler S; Kunert C; Pietschmann K; Wittig A; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2024 May; 150(5):224. PubMed ID: 38693452
[TBL] [Abstract][Full Text] [Related]
68. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
Leahy AB; Elgarten CW; Grupp SA; Maude SL; Teachey DT
Expert Rev Anticancer Ther; 2018 Oct; 18(10):959-971. PubMed ID: 30111196
[TBL] [Abstract][Full Text] [Related]
69. Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia.
Rubinstein JD; Krupski C; Nelson AS; O'Brien MM; Davies SM; Phillips CL
Biol Blood Marrow Transplant; 2020 Nov; 26(11):e280-e285. PubMed ID: 32755637
[TBL] [Abstract][Full Text] [Related]
70. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
71. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Thomas X; Paubelle E
Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
[TBL] [Abstract][Full Text] [Related]
72. CD19 CAR T cell product and disease attributes predict leukemia remission durability.
Finney OC; Brakke HM; Rawlings-Rhea S; Hicks R; Doolittle D; Lopez M; Futrell RB; Orentas RJ; Li D; Gardner RA; Jensen MC
J Clin Invest; 2019 May; 129(5):2123-2132. PubMed ID: 30860496
[TBL] [Abstract][Full Text] [Related]
73. Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
Jacoby E; Bielorai B; Hutt D; Itzhaki O; Adam E; Bar D; Besser MJ; Toren A
Br J Haematol; 2022 May; 197(4):475-481. PubMed ID: 35224724
[TBL] [Abstract][Full Text] [Related]
74. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
Vairy S; Garcia JL; Teira P; Bittencourt H
Drug Des Devel Ther; 2018; 12():3885-3898. PubMed ID: 30518999
[TBL] [Abstract][Full Text] [Related]
75. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
Appl Health Econ Health Policy; 2024 Apr; ():. PubMed ID: 38683438
[TBL] [Abstract][Full Text] [Related]
76. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
[TBL] [Abstract][Full Text] [Related]
77. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Gupta S; Kohorst M; Alkhateeb HB
Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
[TBL] [Abstract][Full Text] [Related]
78. Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia.
Freyer CW
J Adv Pract Oncol; 2018; 9(5):537-544. PubMed ID: 31086690
[TBL] [Abstract][Full Text] [Related]
79. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
[TBL] [Abstract][Full Text] [Related]
80. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
Li N; Li H
J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
